Ads
related to: hemophilia b treatment drugs names and photos list of side effects- Clincal Data & Efficacy
Explore The Clinical Data Of The
Product. View Expert Videos Here.
- Prophylaxis Treatment
Learn About The Prophylactic
Efficacy Of This Treatment.
- Stay In The Know
Sign Up To Receive Product
Updates & Additional Information.
- Prescribing Information
View Prescribing Info To Get
Patients Started On This Treatment.
- Learn About The Pen
View Info About The New Once-Daily
PPx Pen & How To Use It Here.
- How It Works
See How This New Treatment Works.
View The MOA & Watch The Video.
- Clincal Data & Efficacy
Search results
Results From The WOW.Com Content Network
In the US, fidanacogene elaparvovec is indicated for the treatment of adults with moderate to severe hemophilia B (congenital factor IX deficiency) who currently use factor IX prophylaxis therapy; or have current or historical life-threatening hemorrhage; or have repeated, serious spontaneous bleeding episodes; and do not have neutralizing antibodies to adeno-associated virus serotype Rh74var ...
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
[9] [13] Other serious side effects include blood clots which may result in a heart attack, stroke, pulmonary embolism, or deep vein thrombosis. [13] Antibodies may form after long term use such that future doses are less effective. [11] Prothrombin complex concentrate came into medical use in the 1960s. [14]
Hympavzi is the first and only anti-tissue factor pathway inhibitor (anti-TFPI) approved in the U.S. for hemophilia A or B and the first hemophilia medicine approved in the U.S. to be administered via
Etranacogene dezaparvovec, sold under the brand name Hemgenix is a gene therapy used for the treatment of hemophilia B. [ 5 ] [ 6 ] [ 7 ] Etranacogene dezaparvovec is an adeno-associated virus vector-based gene therapy which consists of a viral vector carrying a gene for clotting Factor IX . [ 7 ]
Concizumab, sold under the brand name Alhemo, is a monoclonal antibody used for the treatment of hemophilia A and hemophilia B. [5] [8] It is an anti-tissue factor pathway inhibitor. [5] [8] The most common adverse reactions include injection site reactions and hives (urticaria). [11]
Ad
related to: hemophilia b treatment drugs names and photos list of side effects